Riccardo Soffietti (EAN Programme Committee; Chairman, Department of Neuro-Oncology, University and City of Health and Science Hospital, Turini, Italy) talks to us about the topic of the symposium he participated in entitled: Advances in molecular characterisation and personalised therapies in brain tumours. Part 1 of 2.
Questions
1 What have been the most important recent advances in personalised medicine in brain tumours? (0:12)
2. Which do you see as the most promising therapeutic target in glioblastoma: the glial cells or immune cells? (1:09)
3. Have advances in molecular characterisation allowed us to identify any predictive or prognostic molecular biomarkers? (2:07)
View Part 2 here.
Speaker disclosure: Riccardo Soffietti has nothing to disclose in relation to this video interview.
Filmed at the 4th Congress of the European Academy of Neurology (EAN), Lisbon, Portugal, June 2018.
